[Esketamine Alleviates Postoperative Depressive Symptoms in Frail Elderly Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer: A Randomized Double-Blind Controlled Trial].
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition March 20, 2025 Congli Zhang, Yan Yan, Junjie Ma et al. 1 citation
In a double-blind randomized trial, 82 frail elderly patients undergoing thoracoscopic radical resection of lung cancer received either intravenous esketamine or a placebo (normal saline) during surgery. Those given esketamine had significantly lower depression scores (HAMD-17) at 7 and 30 days after surgery, indicating less postoperative depression. They also reported better sleep quality in the first week and showed higher scores on a cognitive function test (MMSE) in the first month. Esketamine was associated with higher levels of serum BDNF and 5-HT, lower levels of S100β and NSE, reduced use of anesthetic drugs, fewer side effects like nausea and hyperalgesia, and shorter stays in the recovery room and hospital. Esketamine appears to improve postoperative depressive state, sleep, and cognitive function in this vulnerable group.